Literacy Capital (BOOK), the £176m UK private equity investment trust recovering from the write-down and sale of its holding in Cubo Work last month, has disposed of its residual interest in recruitment company Kernel Global for £6.5m. The secondary sale of mostly loan notes comes more than three years after BOOK sold most of its position to Three Hills Capital Partners for £19.7m. It originally invested £2.9m in Kernel between June 2018 and September 2019 which means total proceeds of £26.4m represent an overall return of nine times its original capital and an annual internal rate of return (IRR) of 54.2%. The latest sale was in line with the carrying value at 30 September and so has no impact on net asset value (NAV). “Logan Naidu, CEO of Kernel, has done a fantastic job in building the business and its brands globally since our original investment a little over eight years ago,” said fund manager Richard Pindar. BOOK shares rose 2%, or 6p, to 300p, below the 319p level they stood at before the Cubo announcement.
Matthew Read, senior analyst at QuotedData, said: “Although the residual Kernel sale has been achieved at net asset value and so generates no NAV uplift, a ninefold return on investment and 54.2% IRR are strong returns and illustrate the ability of Literacy Capital’s manager to identify and back successful businesses at an early stage. Given that the remaining Kernel investment offered limited upside, disposing of the asset and recycling the proceeds into debt reduction looks sensible. It also fits with BOOK’s strategy of simplifying its portfolio and concentrating resources on its larger holdings, where the scope for meaningful NAV growth is greatest.”
RTW Biotech Opportunities (RTW) says Windward Bio Group AG (WWB), a Swiss developer of treatments for respiratory and dermatologic diseases accounting for 0.8% of its portfolio at 31 October, saw its shares leap 68% on their flotation on Nasdaq on Friday. Windward sold 10m shares in the initial public offer (IPO) at $17 to raise $175m (£132m) with French pharmaceutical giant Sanofi providing a further $50m at the IPO price. Windward’s lead programme, WIN378, is currently in phase 2/3 trials for asthma and a phase 2 trial for chronic obstructive pulmonary disease. RTW first invested $5.3m in Windward’s series-A funding round in January 2025 and a further $1.7m in a $165m series-B round in May led by Orbimed, manager of Biotech Growth (BIOG).
Separately, the company said net asset value (NAV) fell 1.1% in October versus a 2.9% rise in the Nasdaq Biotech index and 3.8% decline for the Russell 2000 Biotech smaller company index. RTW said it had delivered a 13.9% annualised investment return since launch in October 2019 and remained positive on the medium-term outlook. “We expect biotech M&A to remain elevated, given patent expiries and the cash flows generated by obesity drugs. IPO volumes are normalising and aftermarket performance is healthy. Drug pricing policy uncertainty has largely resolved, and we continue to see limited to no impact from MFN [most favoured nation] pricing on the US businesses of our portfolio companies. AI and the growing contribution of Chinese science are improving productivity in drug discovery, and a growing number of emerging biotechs now have rapidly growing revenues. We expect the current [interest] rate tightening cycle to be shorter and less significant than in previous cycles.”
Matthew Read at QuotedData said: “Windward’s IPO provides a further demonstration of RTW Biotech Opportunities’ ability to identify promising biotech businesses at an early stage. Winward’s first-day closing price represented a near 200% return on cost, although its relatively small portfolio weighting means the immediate impact on NAV will be modest. However, with 10 go-public events and 17 liquidity events so far this year, RTW is benefiting from a marked improvement in the market for biotech exits. This should help address one of the principal concerns weighing on its rating – the ability to realise value from its private investments.”
US Solar Fund (USF) has granted a third extension to the potential buyer assessing its assets. “The provision of additional time to review the operational performance of the remediated assets is believed to be the best option available to the company,” said USF’s board, which now expects the transaction to complete in the first quarter of next year. The £115m investment trust, whose wind-down is being managed by Amber Infrastructure, first disclosed the interested party prepared to pay a “significant premium” for its solar portfolio in May. The shares stand on a 38% discount to net asset value. They have risen 35% in the past six months but have lost nearly half their value over five years.
QuotedData’s Matthew Read said: “Our view hasn’t changed since the last extension to the exclusivity period was announced in October. Yes, this will continue to be frustrating for US Solar Fund shareholders, who have already waited a long time for a resolution, but allowing the prospective buyer more time to assess the performance of the recently remediated assets still looks sensible, particularly if this ultimately helps demonstrate that the problems have been resolved and supports a higher sale price. We continue to think that, with USF in wind-down, a clean exit with greater certainty over the proceeds, rather than an earn-out arrangement, also has to be preferable at this stage. However, we note that regulatory approval is still to be received and, without an agreed price or binding contract, there is still considerable uncertainty.”
Living REIT (LIVE), the £328m social housing and retirement home real estate investment trust, has reassigned 29 of its 30 leases with Auckland Home Solutions after the struggling Durham-based housing association fell into insolvency. The leases have been transferred to Inclusion, a stronger housing association in York. LIVE shares added 0.5p to 71.8p. The 8%-yielder ended last week on a 23% discount to net asset value.
Matthew Read said: “Living REIT’s decision to transfer Auckland’s leases to Inclusion looks like a sensible and proactive move. Financial difficulties among housing providers have been a recurring problem for the supported housing sector, undermining rental income and property valuations. Moving £2.1m of annual rent from a financially troubled provider to one with a stronger regulatory and payment record is a very sensible response, particularly as the company expects no loss of income and sees potential for a valuation uplift. There is, of course, a trade-off in increasing exposure to what is already Living REIT’s largest tenant, but Inclusion’s stronger financial and regulatory standing should reduce overall counterparty risk. More broadly, this illustrates the importance of active asset management in a sector where the financial health of tenants can be just as important as the quality of the underlying properties.”